Market Place
Sourcing Support
Geron Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
19 Dec 2024 //
BUSINESSWIRE
Geron`s RYTELO™ Approved By CHMP For Transfusion-Dependent MDS
13 Dec 2024 //
BUSINESSWIRE
Geron: IMerge Data Shows RYTELO™ Active In Lower-Risk MDS
10 Dec 2024 //
BUSINESSWIRE
Geron to Participate in Evercore ISI HealthCONx Conference
27 Nov 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
21 Nov 2024 //
BUSINESSWIRE
Geron to Participate in Stifel 2024 Healthcare Conference
11 Nov 2024 //
BUSINESSWIRE
Geron Appoints Joseph Eid, M.D. as EVP of R&D
11 Nov 2024 //
BUSINESSWIRE
Geron Corporation Reports Q3 2024 Financial Results & Highlights
07 Nov 2024 //
BUSINESSWIRE
Geron Corporation Announces $375M in Funding with Royalty Pharma
07 Nov 2024 //
BUSINESSWIRE
Geron to Present RYTELO™ Data at ASH in Hematologic Malignancies
05 Nov 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Oct 2024 //
BUSINESSWIRE
Geron to Announce Third Quarter 2024 Financial Results on Nov 7, 2024
15 Oct 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule
19 Sep 2024 //
BUSINESSWIRE
Geron Corp Names Jim Ziegler As Chief Commercial Officer
09 Sep 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Aug 2024 //
BUSINESSWIRE
Geron Corporation Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
BUSINESSWIRE
NCCN Guidelines Now Include Geron`s RYTELO For Lower-Risk MDS Treatment
26 Jul 2024 //
BUSINESSWIRE
Geron Announces Chief Commercial Officer`s Departure In August 2024
23 Jul 2024 //
BUSINESSWIRE
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
18 Jul 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Jun 2024 //
BUSINESSWIRE
FDA signs off on Geron`s long-awaited blood cancer drug Rytelo
08 Jun 2024 //
FIERCE PHARMA
Geron`s RYTELO™ Telomerase Inhibitor Approved For Lower-Risk MDS
07 Jun 2024 //
BUSINESSWIRE
Geron Announces FDA Approval Of RYTELO™ For Treatment Of Lower-Risk MDS
06 Jun 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 May 2024 //
BUSINESSWIRE
Ahead of likely approval, ICER finds Geron’s imetelstat at $250,000 annually
09 May 2024 //
ENDPTS
Geron Reports Q1 2024 Results, Business Highlights
02 May 2024 //
BUSINESSWIRE
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
25 Apr 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Apr 2024 //
BUSINESSWIRE
Geron to Participate at Upcoming Investor Conferences in April
03 Apr 2024 //
BUSINESSWIRE
Geron Corporation Announces Pricing of $150 M Underwritten Offering of
19 Mar 2024 //
BUSINESSWIRE
Geron secures 12-2 AdComm vote in favor of blood cancer drug
15 Mar 2024 //
FIERCE BIOTECH
Geron`s blood disorder drug gets FDA advisers` backing
15 Mar 2024 //
YAHOO FINANCE
US FDA staff raises concerns on Geron`s blood disorder drug
13 Mar 2024 //
REUTERS
Geron Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Feb 2024 //
BUSINESSWIRE
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results
14 Feb 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Jan 2024 //
BUSINESSWIRE
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
12 Jan 2024 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Dec 2023 //
BUSINESSWIRE
Geron Announces IMerge Phase 3 Presentations at ASH
11 Dec 2023 //
BUSINESSWIRE
Geron Announces 50% Enrollment in the Phase 3 Trial Evaluating Imetelstat
06 Dec 2023 //
BUSINESSWIRE
Geron Announces Publication of Results from Phase 3 Evaluating Imetelstat
04 Dec 2023 //
BUSINESSWIRE
Geron Announces Appointment of Gaurav Aggarwal to its Board of Directors
28 Nov 2023 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Nov 2023 //
BUSINESSWIRE
Geron to Participate at Upcoming Investor Conferences in November
07 Nov 2023 //
BUSINESSWIRE
Geron Reports Business Highlights and Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Geron IMerge Phase 3 Presentations Reinforce Durability of Imetelstat
02 Nov 2023 //
BUSINESSWIRE
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
26 Oct 2023 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Oct 2023 //
BUSINESSWIRE
Geron Announces EMA Validation of MAA for Imetelstat
29 Sep 2023 //
BUSINESSWIRE
Geron Announces Appointment of Michelle Robertson as Executive Vice President
11 Sep 2023 //
BUSINESSWIRE
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat
07 Sep 2023 //
BUSINESSWIRE
Geron to Participate in the Baird 2023 Global Healthcare Conference
05 Sep 2023 //
BUSINESSWIRE
Geron Announces FDA Acceptance of New Drug Application for Imetelstat
21 Aug 2023 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Aug 2023 //
BUSINESSWIRE
Geron Reports Business Highlights and Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
27 Jul 2023 //
BUSINESSWIRE
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Jul 2023 //
BUSINESSWIRE
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 Jun 2023 //
BUSINESSWIRE
Geron Announces Submission of NDA to FDA for First-in-Class Telomerase
20 Jun 2023 //
BUSINESSWIRE
